Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

379.68 +7.70 (+2.07%)
Streaming Delayed Price Updated: 2:07 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 165,745
Open 370.12
Bid (Size) 379.58 (40)
Ask (Size) 379.74 (80)
Prev. Close 371.98
Today's Range 369.49 - 380.00
52wk Range 253.95 - 385.22
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
From BeOne Medicines Ltd.
Via Business Wire

Performance

YTD
+22.1%
+22.1%
1 Month
+16.5%
+16.5%
3 Month
+25.5%
+25.5%
6 Month
+2.4%
+2.4%
1 Year
+23.0%
+23.0%

More News

Read More
News headline image
BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
From BeOne Medicines Ltd.
Via Business Wire
News headline image
A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 ↗
Via MarketBeat
News headline image
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
Via The Motley Fool
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
Via The Motley Fool
Topics Initial Public Offering
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
From BeOne Medicines Ltd
Via Business Wire

Frequently Asked Questions

Is BeOne Medicines Ltd. - American Depositary Shares publicly traded?
Yes, BeOne Medicines Ltd. - American Depositary Shares is publicly traded.
What exchange does BeOne Medicines Ltd. - American Depositary Shares trade on?
BeOne Medicines Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BeOne Medicines Ltd. - American Depositary Shares?
The ticker symbol for BeOne Medicines Ltd. - American Depositary Shares is ONC on the Nasdaq Stock Market
What is the current price of BeOne Medicines Ltd. - American Depositary Shares?
The current price of BeOne Medicines Ltd. - American Depositary Shares is 379.68
When was BeOne Medicines Ltd. - American Depositary Shares last traded?
The last trade of BeOne Medicines Ltd. - American Depositary Shares was at 08/25/26 02:07 PM ET
What is the market capitalization of BeOne Medicines Ltd. - American Depositary Shares?
The market capitalization of BeOne Medicines Ltd. - American Depositary Shares is 459.82B
How many shares of BeOne Medicines Ltd. - American Depositary Shares are outstanding?
BeOne Medicines Ltd. - American Depositary Shares has 460B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.